FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to bispecific polypeptide complexes that specifically bind to CD3 and CD19, and can be used in medicine for the treatment of B-cell lymphoma. CD3/CD19 bispecific polypeptide complexes are obtained recombinantly, which contain a combination of four polypeptide sequences: SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28 and SEQ ID NO: 29 or SEQ ID NO: 30.
EFFECT: invention makes it possible to obtain bispecific polypeptide complexes capable of simultaneously binding to CD3 and CD19, T-cells and B-cells and causing subsequent lysis of a malignant CD19-positive B-cell.
13 cl, 23 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| HEAVY CHAIN-ONLY ANTIBODIES THAT BIND TO CD19 | 2019 |
|
RU2824170C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2753882C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
